Scholarlink

Purpose <p>Outcomes of adjuvant (aRT) or salvage radiation therapy (sRT) after radical prostatectomy are under investigation regarding cancer-control outcomes.</p> Methods <p>Relying on the University Cancer Center database elaborating differences in metastasis-free (MFS), cancer-specific (CSS) and overall survival (OS) of aRT vs. sRT-treated patients between 2014–2024. Sensitivity analyses addressed high-risk patients with pN1 and/or Gleason score&#xa0;8–10 and/or pT3–4 stage.</p> Results <p>Of 1862 patients, 7.1% underwent aRT and 93% were in the sRT group. Median PSA at sRT was 0.33 ng/ml. Patients with aRT harbored significantly worse baseline tumor and pathological characteristics such as PSA level (12.0 vs. 7.6 ng/ml), Gleason score&#xa0;9–10 (30% vs.&#xa0;9.8%), D’Amico high risk prostate cancer (97% vs.&#xa0;56%), as well as pT3–4, pN1 and positive surgical margins rates (all <i>p</i> &lt; 0.001). Similar observations were made for high-risk patients. No differences were observed for aRT vs. sRT with 60-month MFS rates of 85.1% vs. 95.4% (hazard ratio [HR] 0.60, <i>p</i> = 0.18). 60-months CSS-rates of 96.8% vs. 99.1% and 60-month OS-rates of 91.0% vs. 89.1% respectively (all <i>p</i> ≥ 0.15). Neither sensitivity analyses of high-risk patients nor multivariable adjusted Cox regression models revealed significant differences regarding MFS, CSS or OS in aRT vs. SRT comparison (all <i>p</i> ≥ 0.05), despite aRT showing qualitatively better OS results.</p> Conclusion <p>Within real-world setting, patients undergoing aRT harbor wore tumor characteristics. However, these differences did not translate into significant differences of mid-term oncological outcomes, relative to sRT patients. Similar observations were made within analyses of high-risk patients with pT3–4 and/or Gleason&#xa0;8–10 and/or pN1 stage, nevertheless aRT showed slightly higher OS rates within this subgroup.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月6日

查看全文
  • Mike Wenzel,
  • Katrin Burdenski,
  • Nikolaos Tselis,
  • Claus Rödel,
  • Christian Brandts,
  • Marit Ahrens,
  • Jens Koellermann,
  • Markus Graefen,
  • Clara Humke,
  • Carolin Siech,
  • Benedikt Hoeh,
  • Severine Banek,
  • Felix K. H. Chun,
  • Philipp Mandel

摘要

Purpose

Outcomes of adjuvant (aRT) or salvage radiation therapy (sRT) after radical prostatectomy are under investigation regarding cancer-control outcomes.

Methods

Relying on the University Cancer Center database elaborating differences in metastasis-free (MFS), cancer-specific (CSS) and overall survival (OS) of aRT vs. sRT-treated patients between 2014–2024. Sensitivity analyses addressed high-risk patients with pN1 and/or Gleason score 8–10 and/or pT3–4 stage.

Results

Of 1862 patients, 7.1% underwent aRT and 93% were in the sRT group. Median PSA at sRT was 0.33 ng/ml. Patients with aRT harbored significantly worse baseline tumor and pathological characteristics such as PSA level (12.0 vs. 7.6 ng/ml), Gleason score 9–10 (30% vs. 9.8%), D’Amico high risk prostate cancer (97% vs. 56%), as well as pT3–4, pN1 and positive surgical margins rates (all p < 0.001). Similar observations were made for high-risk patients. No differences were observed for aRT vs. sRT with 60-month MFS rates of 85.1% vs. 95.4% (hazard ratio [HR] 0.60, p = 0.18). 60-months CSS-rates of 96.8% vs. 99.1% and 60-month OS-rates of 91.0% vs. 89.1% respectively (all p ≥ 0.15). Neither sensitivity analyses of high-risk patients nor multivariable adjusted Cox regression models revealed significant differences regarding MFS, CSS or OS in aRT vs. SRT comparison (all p ≥ 0.05), despite aRT showing qualitatively better OS results.

Conclusion

Within real-world setting, patients undergoing aRT harbor wore tumor characteristics. However, these differences did not translate into significant differences of mid-term oncological outcomes, relative to sRT patients. Similar observations were made within analyses of high-risk patients with pT3–4 and/or Gleason 8–10 and/or pN1 stage, nevertheless aRT showed slightly higher OS rates within this subgroup.